Zacks: Analysts Anticipate Addus Homecare Co. (NASDAQ:ADUS) Will Announce Quarterly Sales of $161.05 Million

Brokerages expect Addus Homecare Co. (NASDAQ:ADUS) to announce sales of $161.05 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Addus Homecare’s earnings, with the highest sales estimate coming in at $166.45 million and the lowest estimate coming in at $157.03 million. Addus Homecare reported sales of $137.63 million during the same quarter last year, which indicates a positive year over year growth rate of 17%. The business is scheduled to issue its next quarterly earnings results on Monday, November 4th.

On average, analysts expect that Addus Homecare will report full year sales of $616.70 million for the current fiscal year, with estimates ranging from $611.08 million to $626.78 million. For the next financial year, analysts expect that the business will report sales of $688.15 million, with estimates ranging from $676.70 million to $712.07 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Addus Homecare.

Addus Homecare (NASDAQ:ADUS) last issued its earnings results on Monday, August 5th. The company reported $0.47 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.47. The company had revenue of $149.69 million during the quarter, compared to the consensus estimate of $146.66 million. Addus Homecare had a return on equity of 8.55% and a net margin of 3.31%.

ADUS has been the subject of several research reports. Raymond James set a $92.00 target price on Addus Homecare and gave the company an “outperform” rating in a research note on Wednesday, August 7th. William Blair reiterated an “outperform” rating on shares of Addus Homecare in a research note on Friday, August 9th. BMO Capital Markets set a $85.00 price target on Addus Homecare and gave the company a “hold” rating in a research note on Wednesday, August 7th. Oppenheimer lifted their price target on Addus Homecare from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Sidoti lifted their price target on Addus Homecare from $84.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $83.44.

In other Addus Homecare news, EVP Laurie Manning sold 990 shares of Addus Homecare stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $83.21, for a total transaction of $82,377.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider W Bradley Bickham sold 15,000 shares of Addus Homecare stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $80.67, for a total transaction of $1,210,050.00. Following the transaction, the insider now directly owns 38,311 shares in the company, valued at approximately $3,090,548.37. The disclosure for this sale can be found here. Insiders have sold a total of 455,990 shares of company stock valued at $33,887,628 in the last quarter. Company insiders own 20.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Addus Homecare by 3.6% during the 2nd quarter. BlackRock Inc. now owns 1,551,759 shares of the company’s stock worth $116,305,000 after buying an additional 54,424 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in shares of Addus Homecare by 4.0% during the 2nd quarter. TimesSquare Capital Management LLC now owns 918,300 shares of the company’s stock worth $68,827,000 after buying an additional 35,570 shares in the last quarter. Invesco Ltd. lifted its position in shares of Addus Homecare by 199.7% during the 2nd quarter. Invesco Ltd. now owns 330,362 shares of the company’s stock worth $24,760,000 after buying an additional 220,140 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Addus Homecare by 8.5% during the 2nd quarter. Royal Bank of Canada now owns 255,645 shares of the company’s stock worth $19,161,000 after buying an additional 20,096 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its position in shares of Addus Homecare by 15.3% during the 2nd quarter. Allianz Asset Management GmbH now owns 235,279 shares of the company’s stock worth $17,634,000 after buying an additional 31,152 shares in the last quarter. 98.74% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ADUS traded down $1.36 during trading hours on Monday, hitting $87.07. The stock had a trading volume of 115,400 shares, compared to its average volume of 109,747. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.84 and a quick ratio of 2.87. The firm has a 50 day simple moving average of $79.93 and a 200-day simple moving average of $70.50. The firm has a market capitalization of $1.15 billion, a P/E ratio of 51.52, a price-to-earnings-growth ratio of 2.78 and a beta of -0.10. Addus Homecare has a 1-year low of $57.94 and a 1-year high of $92.91.

About Addus Homecare

Addus HomeCare Corporation provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates in three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living.

Featured Article: Special Dividends

Get a free copy of the Zacks research report on Addus Homecare (ADUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Addus Homecare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus Homecare and related companies with MarketBeat.com's FREE daily email newsletter.